Biotech company Regeneron (NASDAQ: REGN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 19% year on year to $3.61 billion. Its non-GAAP profit of $9.47 per share was 6.4% above analysts’ consensus estimates.
Is now the time to buy REGN? Find out in our full research report (it’s free for active Edge members).
Regeneron (REGN) Q1 CY2026 Highlights:
- Revenue: $3.61 billion vs analyst estimates of $3.47 billion (19% year-on-year growth, 3.8% beat)
- Adjusted EPS: $9.47 vs analyst estimates of $8.90 (6.4% beat)
- Adjusted EBITDA: $1.15 billion vs analyst estimates of $1.45 billion (32% margin, 20.2% miss)
- Operating Margin: 17.8%, down from 19.5% in the same quarter last year
- Market Capitalization: $69.83 billion
StockStory’s Take
Regeneron's first quarter performance delivered revenue and non-GAAP earnings per share above Wall Street expectations, as management cited strong commercial execution across leading products such as DUPIXENT and EYLEA HD, as well as pipeline advances in oncology and rare diseases. CEO Leonard Schleifer attributed the margin decline to ongoing investments in research, a temporary manufacturing interruption in Ireland, and higher launch costs for new products. Management acknowledged the impact of these factors on overall profitability, noting the company remains focused on long-term growth opportunities.
Looking forward, Regeneron's outlook is shaped by a combination of new product launches, expansion into additional therapeutic areas, and evolving regulatory dynamics. Management highlighted ongoing progress in late-stage programs, with a particular focus on regulatory decisions for EYLEA HD and garetosmab, as well as anticipated milestones in obesity and hematology. CFO Christopher Fenimore cautioned that gross margins may remain pressured in the near term due to the manufacturing ramp-up, but management believes robust demand for DUPIXENT and upcoming pipeline readouts could support future growth. As Dr. Schleifer stated, the company is “well positioned to advance our portfolio and deliver meaningful benefit to patients worldwide.”
Key Insights from Management’s Remarks
Management noted that first quarter performance was driven by robust demand for its core products, ongoing launches in new indications, and rapid pipeline progress, but margin headwinds arose from increased R&D investment and manufacturing challenges.
- DUPIXENT multi-indication growth: The immunology franchise continued to expand, with DUPIXENT showing strong demand across existing and newly approved indications, including allergic fungal rhinosinusitis and chronic spontaneous urticaria in pediatric patients. Management cited broad physician adoption and deeper market penetration as key contributors.
- EYLEA HD adoption accelerates: EYLEA HD saw significant physician uptake following label enhancements and increased dosing flexibility, with sequential demand growth despite typical first quarter seasonality. However, traditional EYLEA sales declined as patients transitioned to the newer formulation, and management flagged further biosimilar competition ahead.
- Oncology momentum from Libtayo: Libtayo's performance was fueled by uptake in newly launched adjuvant cutaneous squamous cell carcinoma (CSCC) and gains in advanced non-small cell lung cancer. Early feedback on the adjuvant CSCC indication has been positive, positioning Libtayo as a preferred option among eligible patients.
- Pipeline advances and regulatory updates: The quarter featured notable pipeline progress, including FDA approval of Otarmeni for genetic hearing loss (offered free to eligible patients), positive Phase III data for cemdisiran in myasthenia gravis, and regulatory filings for garetosmab in rare disease. Management expects additional regulatory decisions and trial readouts in the coming quarters.
- Margin pressure from investments and manufacturing: Operating margin declined as Regeneron increased R&D spending on late-stage programs and absorbed costs tied to a temporary manufacturing disruption in Ireland. Management said production is resuming and expects full recovery by the end of the next quarter, but near-term margins will remain affected.
Drivers of Future Performance
Regeneron's forward outlook centers on expanding its core franchises and advancing pipeline programs, while navigating near-term margin pressures and competitive shifts.
- Pipeline catalysts and launches: Management expects upcoming regulatory decisions for EYLEA HD’s prefilled syringe and garetosmab in rare disease to shape near-term revenue, while late-stage readouts in obesity (olatorepatide) and oncology could support longer-term growth.
- Margin recovery and manufacturing normalization: Regeneron anticipates that gross margins will improve as manufacturing in Ireland returns to normal, but cautioned that increased R&D and launch expenses could continue to weigh on overall profitability in the short term.
- Competitive and regulatory headwinds: The company flagged ongoing risks from biosimilar competition for EYLEA, evolving drug pricing regulations, and the need for successful collaboration with Sanofi on future DUPIXENT lifecycle management as factors that could influence growth trajectories.
Catalysts in Upcoming Quarters
Looking ahead, key developments to watch include (1) the FDA’s decision on EYLEA HD’s prefilled syringe and garetosmab in rare disease, (2) the pace of commercial adoption for new DUPIXENT and Libtayo indications, and (3) manufacturing normalization at the Ireland facility. Progress on late-stage obesity and hematology trials will also be important markers of execution.
Regeneron currently trades at $680.03, down from $731.77 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
High Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
